Close Menu

Clostridium difficile

Since moving to rapid molecular testing, the lab has doubled its billable test volume, largely through increasing clients for its outreach lab services.

Worcester Polytechnic Institute researchers are developing an inexpensive handheld platform that could provide C. difficile test results in minutes.

Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.

The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.

The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.

The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.

Pages